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RGS9 Modulates Dopamine
Signaling in the Basal Ganglia
pensatory adaptation that diminishes drug respon-
siveness.
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Melvin I. Simon,4 and Eric J. Nestler1,3,* G protein  subunits (reviewed in Dohlman and Thorner,
1Department of Psychiatry and Center for Basic 1997; Berman and Gilman, 1998; De Vries et al., 2000).
Neuroscience RGS proteins can thus dampen or help terminate G
The University of Texas Southwestern Medical protein-mediated signaling. In addition, RGS proteins
Center have been shown to alter the kinetics of G protein signal-
Dallas, Texas 75390 ing (Zerangue and Jan, 1998) and may even function
2 Department of Molecular, Cellular, and as effector molecules in certain signaling networks (De
Developmental Biology Vries and Farquhar, 1999). As a result, RGS proteins
3 Laboratory of Molecular Psychiatry exert complex effects on G protein signaling. While RGS
Yale University proteins have been shown to negatively modulate G
New Haven, Connecticut 06508 protein-coupled neurotransmitter responses in cultured
4 Department of Biology neurons (Saugstad et al., 1998), the net effect of RGS
California Institute of Technology proteins in an intact neural system remains largely unex-
Pasadena, California 91125 plored.
5 Department of Pharmacology RGS proteins differ in their size, composition, and
Virginia Commonwealth University tissue distribution, but all members contain a conserved,
Richmond, Virginia 23298 approximately 120 amino acid sequence, referred to as
6 Department of Pharmacology and Neuroscience the RGS domain. Since their initial description, the RGS
University of North Texas Health Science Center family of proteins has grown rapidly and includes homo-
Fort Worth, Texas 76107 logs throughout the animal and fungal kingdoms (Ross
7 Department of Genetics and Wilkie, 2000). To date, at least 25 mammalian gene
Harvard Medical School products containing the core RGS domain have been
Belmont, Massachusetts 02478 identified. Numerous RGS genes are expressed in the
brain with highly region-specific expression patterns
(Gold et al., 1997).
The expression pattern for one RGS family member,
Summary RGS9, is particularly striking. The RGS9 gene gives rise
to two products, RGS9-1 and RGS9-2, via alternative
Regulators of G protein signaling (RGS) modulate het- splicing (He et al., 1998; Rahman et al., 1999; Zhang et
erotrimeric G proteins in part by serving as GTPase- al., 1999). Each splice variant displays highly specific
activating proteins for G subunits. We examined a and nonoverlapping tissue distribution. RGS9-1 is ex-
role for RGS9-2, an RGS subtype highly enriched in pressed exclusively in retina, while RGS9-2 is highly
striatum, in modulating dopamine D2 receptor func- enriched in striatal regions of brain, which include dorsal
tion. Viral-mediated overexpression of RGS9-2 in rat striatum (caudoputamen), ventral striatum (nucleus ac-
nucleus accumbens (ventral striatum) reduced loco- cumbens), and olfactory tubercle, with very low levels
motor responses to cocaine (an indirect dopamine ag- of expression seen throughout the rest of brain or in
onist) and to D2 but not to D1 receptor agonists. Con- peripheral tissues. The striatal-enriched expression of
versely, RGS9 knockout mice showed heightened RGS9-2 and its localization in medium spiny projection
locomotor and rewarding responses to cocaine and re- neurons (Thomas et al., 1998) suggests that it has a role
lated psychostimulants. In vitro expression of RGS9-2 in dopamine-mediated behavior. One feature of striatal
in Xenopus oocytes accelerated the off-kinetics of D2 neurons is their rich innervation by dopamine and high
receptor-induced GIRK currents, consistent with the levels of expression of dopamine receptors (Aizman et
in vivo data. Finally, chronic cocaine exposure in- al., 2000; Graybiel, 2000). D2 receptors in the nucleus
creased RGS9-2 levels in nucleus accumbens. Together, accumbens are particularly important in mediating the
these data demonstrate a functional interaction be- locomotor-activating and rewarding effects of psycho-
tween RGS9-2 and D2 receptor signaling and the be- stimulant drugs of abuse, such as cocaine and amphet-
havioral actions of psychostimulants and suggest that amine (Self and Nestler, 1998; Wise, 1998; Koob, 1999).
psychostimulant induction of RGS9-2 represents a com- The goal of the present study was to explore a func-
tional relationship between RGS9-2 and D2 receptors
and psychostimulant action in the nucleus accumbens.*Correspondence: eric.nestler@utsouthwestern.edu
8These authors contributed equally to this work. We describe several experiments undertaken to under-
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stand RGS9-2 function in vivo using both overexpres-
sion of the protein by viral-mediated gene transfer in
rats and deletion of the protein in RGS9 knockout mice.
Results of these experiments support an inhibitory influ-
ence of RGS9-2 on D2 receptor signaling and on the
behavioral effects of psychostimulants and suggest a
role for RGS9-2 in aspects of psychostimulant addiction.
Results
Inhibition of Dopamine D2 Receptor-Mediated
Locomotor Responses upon
Overexpression of RGS9-2
As a first step in testing the hypothesis that RGS9-2
modulates dopaminergic neurotransmission, we over-
expressed the protein specifically in the nucleus accum-
bens (Figure 1A) using a herpes simplex virus (HSV)
system demonstrated to be effective for in vivo gene
transfer (Carlezon et al., 1997, 1998). This treatment was
found to result in a 80% increase in RGS9-2 levels
compared to basal levels of the protein (Figure 1A). As
shown previously for other HSV-expressed proteins, we
found that RGS9-2 overexpression was transient (maxi-
mal 3–4 days after virus injection) and not associated
with detectable toxicity. The consequence of RGS9-2
overexpression on behavioral responses to dopamine
was assessed in a circling model, which has been used
for more than 30 years as a standard test of dopaminer-
gic function (Ungersted and Arbuthnott, 1970). For ex-
ample, unilateral lesions of midbrain dopamine neurons
that innervate the striatum, followed by administration
of apomorphine (a nonselective dopamine receptor ago-
nist), causes dramatic circling behavior of the animal
away from the side of the lesion. This is interpreted as
RGS9-2 mRNA). Inset shows Western blots labeled for RGS9-2.
Lanes 1 and 2, nucleus accumbens from an HSV-RGS9-2-injected
animal (lane 2) and the contralateral side injected with HSV-LacZ
(lane 1). Levels of RGS9-2 on the HSV-RGS9-2-injected side were
82%  5% higher than on the contralateral control side (mean %
of control  SEM, n  4, p  0.05 by t test). Lanes 3–5, PC12 cells
infected with HSV-RGS9-2 (lane 4) or HSV-LacZ (lane 3); lane 5
shows protein extract from normal striatum as a positive control.
(B) (Left) HSV-RGS9-2, HSV-RGS9-1, HSV-RGS4, or sucrose vehicle
(VEH) was unilaterally injected in the medial nucleus accumbens of
rats; HSV-LacZ was injected on the other side as a control. On days
3 and 4 after surgery, at which time transgene expression is maximal,
animals were challenged with apomorphine (1 mg/kg sc) and circling
behavior was measured. Data were calculated as % of total turns
away from HSV-LacZ during a 40 min test period (n  6–12). No
rotational bias would be indicated as 50% on this scale. Asterisk,
significantly different from VEH (p  0.01 by 2 test). (Right) Animals
received HSV-RGS9-2, HSV-RGS9-1, or VEH injections on one side
of the nucleus accumbens, and HSV-LacZ on the other side, and
then challenged with the D2-selective agonist quinpirole (1 mg/kg
i.p.) or the D1-selective agonist SKF81297 (3 mg/kg s.c.) (n  8).
Quinpirole and SKF81297 produced equivalent degrees of general
locomotor activity (300 total rotations in 40 min; not shown). Aster-
isk, significantly different from VEH (p  0.01 by 2 test).
Figure 1. Effect of HSV-Mediated Overexpression of RGS9-2 on Be- (C) Animals received bilateral injections of HSV-RGS9-2 or HSV-
havioral Responses to Dopaminergic Agonists LacZ, and 3 and 4 days later cocaine (10 or 20 mg/kg i.p.)-induced
(A) Sections of rat brain show highly localized overexpression of locomotor activity was measured. Each point represents the mean
RGS9-2 mRNA in the medial aspect of the nucleus accumbens by SEM number of ambulatory counts recorded in 10 min bins over a
in situ hybridization in a representative animal 3 days after injection 2 hr test period. Asterisk, significantly different from HSV-LacZ (p 
of HSV-RGS9-2 into this brain region (arrows indicate overexpressed 0.05 by t test).
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being due to supersensitivity of dopamine receptors on subtype expresses enkephalin, whereas the other ex-
presses substance P and dynorphin (Aizman et al., 2000;the denervated side. In contrast, apomorphine does not
induce circling in a normal animal. Graybiel, 2000). While the precise functional roles played
by these two subtypes of neurons remain incompletelyIn the present study, HSV-RGS9-2 was injected on
one side of the nucleus accumbens, and HSV-LacZ was understood, there is substantial evidence that both con-
tribute to the locomotor-activating and rewarding ac-injected on the other. Apomorphine challenge induced
circling in the animals with a strong directional bias: tions of psychostimulants (Graybiel, 2000; Self and
Nestler, 1998). We used a double-labeling in situ hybrid-animals rotated in a direction toward the side of RGS9-2
overexpression (Figure 1B). These results suggest an ization protocol to study the distribution of RGS9-2 be-
tween these two subtypes of nucleus accumbens neu-imbalance in dopaminergic neurotransmission, with the
side overexpressing RGS9-2 being less responsive than rons. As shown in Figure 2, RGS9-2 is present in a
majority of both enkephalin and substance P neu-the other. Overexpression of RGS9-1 induced a similar
degree of circling, whereas animals injected with vehicle rons. In general, enkephalin neurons express high lev-
els of D2 receptors, whereas dynorphin/substance Pshowed minimal circling and no rotational bias. Similarly,
little circling and no rotational bias was observed when neurons express high levels of D1 receptors (Aizman et
al., 2000; Graybiel, 2000). Consistent with these patternsRGS4, another RGS protein prevalent in striatum (Gold
et al., 1997), was overexpressed unilaterally in nucleus of expression, double-labeling immunohistochemistry
confirmed that a majority of D2 neurons also expressaccumbens (Figure 1B).
To determine whether the effect of RGS9-2 on re- RGS9-2 (not shown). Together, these anatomical data
indicate that while RGS9-2 is broadly expressed in nu-sponses to apomorphine was specific to a particular
dopamine receptor subtype, we tested the effect of D1- cleus accumbens and dorsal striatum, it is heavily colo-
calized in neurons that express D2 receptors. Thisselective and D2-selective dopamine receptor agonists
on circling behavior of animals unilaterally injected with complements the behavioral-pharmacological data to
further indicate an association between RGS9-2 andHSV-RGS9-2 into nucleus accumbens, with HSV-LacZ
again injected on the other side. Animals administered signaling via dopamine D2 receptors.
quinpirole, a D2-selective agonist, showed similar rota-
tional bias as seen for apomorphine (Figure 1B), al- Enhanced Locomotor Responses to Psychostimulants
though the total amount of circling was not as great in RGS9 Knockout Mice
as for apomorphine. In contrast, animals administered To complement our studies of RGS9-2 overexpression
SKF81297, a D1-selective agonist, showed no rotational in rats, we characterized locomotor responses to psy-
bias, although the animals displayed a general increase chostimulants in RGS9 knockout mice. Consistent with
in locomotor activity that was comparable to that seen the overexpression data in rats, we found that mice
with quinpirole. The findings indicate that the effect of with a null mutation in the RGS9 gene show augmented
RGS9-2 on dopaminergic neurotransmission was selec- locomotor activation in response to amphetamine (Fig-
tive for the D2 receptor. Quinpirole and SKF81297 had ure 3A). This enhanced responsiveness was apparent
similar effects in animals injected with HSV-RGS9-1, at lower doses of amphetamine (1–2 mg/kg), while a
indicating that the unique C-terminal tail of RGS9-2 is higher dose (5 mg/kg) elicited similar responses in the
not required for these behavioral effects. mutants and wild-type littermates. There was no differ-
ence between mutant and wild-type mice in baseline
Inhibition of Cocaine-Induced Locomotor Activity locomotor activity throughout a 30 min habituation pe-
upon Overexpression of RGS9-2 riod (not shown) or in response to saline injections (Fig-
Psychostimulants, such as cocaine, induce locomotor ure 3A). Figures 3B and 3C show, respectively, that
activity via actions on D2 and D1 dopamine receptors, RGS9 knockout mice also exhibit increased locomotor
an action mediated in large part via the nucleus accum- responses to cocaine as well as to the direct dopamine
bens. It was, therefore, of interest to study the effect of receptor agonist apomorphine. This enhanced behav-
RGS9-2 overexpression in this brain region on locomo- ioral responsiveness to dopamine agonists in the RGS9
tor responses to cocaine. As shown in Figure 1C, bilat- knockouts is consistent with enhanced biochemical re-
eral overexpression of RGS9-2 in nucleus accumbens sponsiveness as well. The highly selective D2 agonist
had no effect on baseline locomotor activity but signifi- quinelorane produced a 52% 4% (n 4; p 0.025 by
cantly attenuated the ability of a moderate dose of co- t test) greater inhibition of forskolin-stimulated adenylyl
caine (10 mg/kg i.p.) to stimulate locomotion in these cyclase activity in striatal extracts from RGS9 knockout
animals compared to control animals. This effect of mice compared to their wild-type littermate controls.
RGS9-2 could be overcome by a higher dose of cocaine Repeated exposure to psychostimulants causes pro-
(20 mg/kg), which induced similar levels of locomotor gressively greater locomotor activity, a phenomenon
activity in animals injected with HSV-RGS9-2 or HSV- called locomotor sensitization. To study locomotor sen-
LacZ. sitization in RGS9 mutant mice, we repeatedly adminis-
tered cocaine at a low dose (7.5 mg/kg). As shown in
Figure 3D, this dose of cocaine, upon initial exposure,Cellular Localization of RGS9-2 in Nucleus Accumbens
The nucleus accumbens, like the striatum as a whole, caused relatively small increases in locomotor activity
that were indistinguishable between RGS9 knockoutcontains two major subtypes of medium spiny projection
neurons, which together comprise 90%–95% of the neu- mice and their wild-type littermates. Repeated cocaine
administration produced significant locomotor sensiti-rons in this region. These neuronal subtypes can be
differentiated by the neuropeptide they express; one zation in both wild-type and RGS9 mutant mice (locomo-
Neuron
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Figure 2. Cellular Localization of RGS9 in Nucleus Accumbens
Double-labeling flourescent in situ hybridization of rat striatum demonstrates RGS9-2 expression in both enkephalin and substance P
neurons.
(A–C) Representative low-power photomicrographs of fluorescent in situ hybridization to RGS9 (A), enkephalin (B), and substance P (C) mRNA
via biotin-labeled (Cy3-RGSS9; red) and digoxigenin-labeled (FITC-enkephalin and substance P; green) riboprobes in coronal sections of
nucleus accumbens.
(D–G) Representative high-power, confocal photomicrographs of sections double-labeled for RGS9 and enkephalin (D and E) or for RGS9 and
substance P (F and G). Cells single-labeled for (1) RGS9 are indicated by open arrowheads and for (2) enkephalin or substance P by solid
arrowheads. Cells double-labeled for RGS9 and either enkephalin or substance P are indicated by arrows; for clarity not all cells are highlighted.
RGS9-2 was roughly equally distributed between these two cell types: 65.3%  1.2% of enkephalin cells are positive for RGS9-2; 65.4% 
3.1% of substance P cells are positive for RGS9-2 (from analysis of 250 cells/rat, n  3 rats). Scale bars equal 190 m in (A)–(C) and 33
m in (D)–(G).
tor activity was greater on day 5 compared to day 1), but whether mice lacking the protein show normal levels of
the degree of sensitization was markedly potentiated in D1 and D2 dopamine receptors or whether levels of
the RGS9 knockouts. the receptors are abnormal in the mutant mice due to
developmental compensations. Therefore, direct ra-
Enhanced Rewarding Effects of Cocaine in RGS9 dioligand binding studies were performed to compare
Knockout Mice the expression levels of D1-like and D2-like dopamine
To determine whether the rewarding effects of cocaine receptors in the striatum of wild-type and RGS9-2 null
are also altered in RGS9 mutant mice, we used the mice. The D1-like selective radioligand, 3H SCH 23390,
conditioned place preference test, a classical condition- was used to quantify D1 receptors; the D2-like selective
ing paradigm in which animals learn to prefer an environ- radioligand, 125I-IABN, was used to quantify D2-like re-
ment associated with drug exposure (Wise, 1998). Both ceptors (Luedtke et al., 2000). These binding studies
wild-type and RGS9 knockout mice showed no baseline showed that there was no difference in the level of ex-
preference for either side of the test chambers prior to pression of D1 or D2 receptors between wild-type and
cocaine administration, and both developed significant knockout mice (Table 1).
place conditioning after training with cocaine (Figure
3E). Notably, the RSG9 mutants showed more than dou-
Increased RGS9 Expression in Brain by Chronicble the degree of place conditioning compared to their
Cocaine Administrationwild-type littermates to a moderate dose of cocaine (10
To further characterize a possible role for RGS9-2 inmg/kg), with no apparent difference observed at a higher
mediating responses to psychostimulants, we examineddose (15 mg/kg). Mice heterozygote for the RGS9 dele-
the ability of cocaine to alter levels of RGS9-2 expressiontion showed intermediate place conditioning to cocaine
in striatum. Levels of RGS9 immunoreactivity were ana-(not shown). These results indicate greater sensitivity to
lyzed by Western blotting, using a polyclonal anti-RGS9the rewarding effects of cocaine, as seen for locomotor
antibody, which detects a protein band (76 kDa) thateffects of the drug, in the absence of the RGS9 gene.
corresponds to the calculated size of RGS9-2, is striatal-
enriched, and is absent in striatal extracts from RGS9Normal Dopamine Receptor Levels in RGS9
null mice. Chronic administration of cocaine for 7 daysNull Mice
produced a small, but statistically significant, increaseGiven the influence of RGS9-2 on dopamine signaling
in the nucleus accumbens, it was important to determine in levels of RGS9-2 immunoreactivity in the nucleus ac-
RGS9 Modulates Dopamine Signaling
945
Figure 3. Behavioral Responses of RGS9 Knockout Mice to Psychomotor Stimulants
(A–C) Total locomotor activity scores of RGS9 knockout mice (/) and their wild-type littermates (/) over 30 min after saline (Sal) or single
doses of (A) amphetamine (Amph; 1, 2, or 5 mg/kg i.p.), (B) cocaine (Coc; 10 or 20 mg/kg i.p.), or (C) apomorphine (Apo; 1 mg/kg i.p.). Data
are expressed as mean  SEM photocell disruptions (/, n  6–12 mice in each group). Asterisk, significantly different from saline (A and
B) or baseline (C); dagger, significantly different from wild-type (p  0.05, ANOVA followed by Fisher test).
(D) RGS9 knockout mice and their wild-type littermates were given daily injections of saline for 3 days (S1–S3) followed by daily injections of
cocaine (7.5 mg/kg) for 5 days (C1–C5). Locomotor activity was measured for 10 min after each injection. Data are expressed as mean 
SEM photocell disruptions over the 10 min test period. Wild-type (n  11) and mutant (n  13) mice showed small increases in locomotor
activity after the first dose of cocaine, with no difference apparent between the two genotypes. Both groups of mice also showed significantly
greater locomotor responses to the fifth dose of cocaine compared to the first dose (i.e., sensitization) (p  0.05, ANOVA and t test), although
the knockouts showed significantly greater levels of sensitization (p  0.05, ANOVA and t test).
(E) Place conditioning to cocaine (10 or 15 mg/kg) in RGS9 knockout mice and their wild-type littermates. Data are expressed as the mean 
SEM time spent on drug-paired side minus that on saline-paired side, which provides a measure of place conditioning. Neither genotype
showed a significant baseline preference for either side of the apparatus before conditioning, but both developed a significant place preference
after cocaine training (p  0.05 ANOVA and Fisher). In addition, RGS9 knockouts showed significantly greater place conditioning to cocaine
at the 10 mg/kg dose than wild-type mice (p  0.05 by ANOVA and Fisher test), a difference not seen at the 20 mg/kg dose.
cumbens as well as in the dorsal striatum (Figure 4A).
This effect required repeated cocaine administration,
Table 1. Comparison of D1-like and D2-like Dopamine Receptor since no change was observed after acute exposure to
Binding in the Striatum of Wild-Type and RGS9 Knockout Mice the drug (97% 7% and 99% 6% of control in nucleus
Ligand Kd (nM) Bmax (fmol/mg protein) accumbens and dorsal striatum, respectively; n  7). In
addition, chronic cocaine administration did not alter3H-SCH23390
levels of RGS9-2 mRNA in either the nucleus accumbens
RGS9-2 (/) 0.79  0.10 629  104 or dorsal striatum as determined by in situ hybridization
RGS9-2 (/) 0.88  0.08 616  132 (not shown).
125I-IABN We next examined RGS9-2 levels in rats after cocaine
self-administration. Interestingly, chronic self-adminis-RGS9-2 (/) 0.012  0.001 173  35
tration of cocaine causes an even greater induction ofRGS9-2 (/) 0.014  0.001 185  12
RGS9-2 levels in striatum than observed after investiga-
Radioligand binding techniques were used to determine the dissoci-
tor-administered drug (Figure 4B). This greater effectation constant (Kd) and the maximum density (Bmax) of dopamine
was not due to the increased dose or duration of cocainereceptors in RGS9 knockout mice (/) and their wild-type lit-
exposure in the self-administering animals, since inves-termates using a radioligand selective for either D1-like (3H-SCH
23390) or D2-like (125I-IABN) dopamine receptors. Data are ex- tigator-administered cocaine of a dose and duration that
pressed as means  SEM (n  3–5 animals/group). Equivalent re- mirrors self-administration led to the same smaller in-
sults were obtained in two additional experiments on separate crease in RGS9-2 levels (not shown). As with investiga-
groups of animals.
tor-administered cocaine, self-administration of cocaine
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cal responses in striatal neurons, and the Kir3.1/Kir3.2
channel subtypes are widely expressed in brain includ-
ing striatum (Karschin et al., 1996). When D2 receptors
and GIRK channels are heterologously expressed in oo-
cytes, activation of the receptors by dopamine causes
a time- and dose-dependent activation of an inward
current (Figures 5A and 5B). Coexpression of RGS9-2
significantly accelerated both the on- and off-kinetics
of D2 responses but had no effect on the amplitude of
the current. This is similar to the effect of RGS9-2 and
other RGS proteins on several G protein-coupled recep-
tors (Kovoor et al., 2000). To examine the effect of G	5
on RGS9-2 function, we repeated the above experiment
after reducing the amount of RGS9-2 cRNA injected per
oocyte (from 10 ng to 5 ng). At this level of RGS9-2 cRNA,
the deactivation rate was not significantly different from
control. However, we found that coexpression of G	5
with RGS9-2 significantly accelerated the speed of GIRK
deactivation when compared to RGS9-2 alone (Figure
5C, p  0.05). Expression of G	5 in the absence of
RGS9-2 had no effect on GIRK kinetics (not shown),
indicating the G	5 functions to enhance the action of
RGS9-2 on dopamine receptor-elicited GIRK kinetics.
Thus, RGS9-2 and G	5 appear to modulate dopamine
receptor-GIRK signaling in a manner that is equivalent
to the way they affect m2 muscarinic acetylcholine re-
Figure 4. Regulation of RGS9-2 Immunoreactivity by Chronic Co- ceptor coupling to GIRK channels (Kovoor et al., 2000).
caine Administration The functional activity of RGS9-2 when expressed alone
(A) Rats were treated daily with saline or cocaine (20 mg/kg i.p.) for is not due to endogenous G	5 expressed by Xenopus
7 days; the following day levels of RGS9-2 were measured in extracts
oocytes, which contain no detectable G	5 immunoreac-of nucleus accumbens (NAc) and dorsal striatum (caudate-putamen
tivity (Kovoor et al., 2000).or CP) by Western blotting. Data are expressed as mean  SEM of
Note that the deactivation rates for the control groupsaline-treated animals (n 15). The inset shows representative lanes
of resulting blots. Asterisk, significantly different from saline (p  and the group expressing RGS9-2 in Figure 5B are faster
0.05 by t test corrected for multiple comparisons). than the deactivation rates for the corresponding groups
(B) Rats were allowed to self-administer cocaine or saline daily for in Figure 5C. This is because the data for the two figures
4 hr for a period of 15 days and were used the day after the last
were generated at different times from oocytes obtainedself-administration session. Striatal dissections were then subjected
from different donors. We have observed that the GIRKto Western blotting for RGS9-2, RGS7, RGS11, or G	5. Data are
deactivation rates measured in oocytes from one donorexpressed as mean  SEM of saline-administering animals (n 
12). The inset shows representative lanes of resulting blots. Asterisk, can be significantly different from the rates measured
significantly different from saline (p  0.05 by t test corrected for in an identical experiment with oocytes from another
multiple comparisons). donor. Therefore, comparisons between different exper-
imental groups are always made using oocytes from the
same donor. RGS proteins consistently accelerate the
failed to alter RGS9-2 mRNA levels (not shown). Cocaine deactivation kinetics of receptor-GIRK coupling across
regulation of RGS9-2 showed some specificity for this donors, although the mean deactivation rates of the
protein, since no effect was observed on two related RGS-expressing oocyte groups may be significantly dif-
RGS proteins expressed in striatum, RGS7 or RGS11, ferent from donor to donor.
or on the G protein subunit, G	5 (Figure 4B). This subunit
is of particular interest, because it has been reported
Discussionto uniquely associate with RGS9-1 in retina (Kovoor et
al., 2000; Martemyanov and Arshavsky, 2002; Nair et al.,
The highly enriched expression of RGS9-2 in striatum2002), although a specific association with RGS9-2 has
and the prevalence of dopamine neuromodulation in thisyet to be established.
structure suggest that RGS9-2 could serve specialized
functions for striatal neurons and modulate signaling
through dopamine receptors. We have tested this hy-Effect of RGS9-2 on Kinetics of Dopamine D2
Receptor Signaling pothesis in vivo, using several well-established be-
havioral paradigms for dopamine function. Our resultsWe used dopamine-evoked currents, mediated by in-
wardly rectifying K channels (GIRKs), recorded from indicate that overexpression of RGS9-2 diminishes sen-
sitivity to the behavioral effects of dopamine agonists,Xenopus oocytes coexpressing functional Kir3.1/Kir3.2
channel heteromultimers along with the dopamine D2 while loss of RGS9 has the opposite effect. These ac-
tions of RGS9-2 seem most related to the D2 class ofreceptor to study the direct influence of RGS9-2 on D2
receptor signaling. Regulation of GIRK channels is one dopamine receptor, which is not surprising since the D2
receptor signals via Gi are known to be influenced bymechanism by which D2 receptors produce physiologi-
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RGS proteins, while the D1 receptor signals via Gs are
known to be insensitive to most RGS proteins. Impor-
tantly, loss of RGS9-2 increases an animal’s sensitivity
to the behavioral effects of cocaine, whereas overex-
pression of RGS9-2 has the opposite effect. Moreover,
chronic administration of cocaine increases levels of
RGS9-2 in striatum. Together, these results suggest a
role for RGS9-2 in mediating some of the functional
changes in dopamine signaling induced in striatum after
chronic cocaine exposure.
Circling behavior or rotation in rodents has been used
for more than 30 years as a model system in which
to study dopaminergic function in the basal ganglia. A
functional imbalance in the dopaminergic system be-
tween the two sides of the brain, followed by administra-
tion of a dopamine agonist, results in circling: it is in-
terpreted that the animal turns away from the side of
higher dopaminergic activity. For example, upon unilat-
eral lesioning of dopamine neurons with 6-hydroxydopa-
mine (a dopaminergic neurotoxin), animals turn away
from the lesioned side when challenged with apomor-
phine, a D1/D2 mixed receptor agonist (Ungersted and
Arbuthnott, 1970). This circling is thought to be caused
by greater sensitivity of striatal neurons on the lesioned
side to dopamine stimulation, although the mechanism
underlying this functional supersensitivity has remained
unknown (Schwarting and Huston, 1996).
In the present study, we used this established and
highly reproducible behavioral response to dopaminer-
gic agents to test the hypothesis that RGS9-2 may alter
dopaminergic neurotransmission in striatum. Unilateral
injections of HSV-RGS9-2 into the nucleus accumbens
caused circling behavior to apomorphine. This is a strik-
ing finding, because apomorphine does not induce cir-
cling in a normal animal, and only dramatic manipula-
tions (such as unilateral lesions of the dopamine system)
have previously been shown to induce circling behavior.Figure 5. Effect of RGS9-2 on Kinetics of Dopamine D2 Receptor
These results establish a robust effect of RGS9-2 over-Signaling in Xenopus Oocytes
expression on the balance of dopaminergic sensitivity(A and B) Control (Con) oocytes were injected with 1 ng of cRNA
on the two sides of the brain. More specifically, thefor the dopamine D2 receptor, and 0.02 ng of cRNA each for GIRK1
results suggest that RGS9-2 overexpression decreasesand GIRK2 channels. Another group of oocytes (RGS) was in addi-
tion injected with 10 ng of cRNA for RGS9-2. sensitivity to dopamine receptor activation. This effect
(A) Representative traces of dopamine-evoked GIRK currents. The of RGS9-2 was specific for dopamine D2 receptors,
solid horizontal line above the traces represents dopamine applica- since it was seen after administration of a D2-selective
tion. The traces were normalized to the amplitude of the response agonist, but not a D1-selective agonist. Moreover, the
just prior to dopamine wash off.
effect of RGS9-2 was not a nonspecific effect of overex-(B) Comparison of the deactivation (1/
deactivation) rate constants de-
pressing an RGS protein per se, since overexpressionrived from the exponential fits of the deactivation phase of the
of RGS4, which is also highly expressed in nucleus ac-dopamine-evoked GIRK currents in the two oocyte groups. Data
are expressed as means  SEM from 4–7 oocytes from the same cumbens, had no effect on circling behavior. It will be
oocyte donor. Similar results were repeated in oocytes from two interesting to examine in future studies what feature of
other donors. The mean steady-state current amplitudes in nA  RGS9-2 is required to elicit this effect (for example, its
SEM for the oocyte groups were as follows: control, 708  135; RGS domain or any of several other domains [GGL, DEP]RGS9-2 alone, 1206  157*; asterisk, significantly different from
contained within this RGS subtype [Ross and Wilkie,Con (by p  0.01 by t test).
2000]).(C) Control (Con) oocytes were prepared as described for (A) and
Further evidence for a functional connection between(B). The other oocyte groups were injected in addition with RGS9-2
cRNA (5 ng) alone or RGS9-2 cRNA (5 ng) and G	5 cRNA (10 ng). RGS9-2 and D2 receptors was the finding that the two
The figure shows a comparison of the deactivation (1/
deactivation) rate proteins show prominent coexpression within striatum.
constants derived from the exponential fits of the deactivation Thus, RGS9-2 was present in a large fraction of D2
phases of the dopamine-evoked GIRK currents in the three oocyte
receptor-containing neurons. We also directly studiedgroups. Data are expressed as means  SEM from 4–6 oocytes
interactions between RGS9-2 and D2 receptors in Xeno-from the same oocyte donor; similar results were repeated in oo-
pus oocytes, where expressed GIRK channels respondcytes from a second donor. The mean steady-state current ampli-
to Gi activation; this assay has been used widely totudes in nA  SEM for the different oocyte groups were as follows:
Con, 452  73; RGS, 187  54; RGS  G	5, 88  13. Asterisk, study Gi-coupled pathways (reviewed in Zerangue and
significantly different from Con and RGS groups (p  0.01 by t test). Jan, 1998; Kovoor and Lester, 2002). Coexpression of
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RGS9-2 accelerated both the on- and off-kinetics of self-administration of the drug. This effect was specific
for RGS9-2, since no change was observed in levels ofD2-mediated channel activation but did not alter the
amplitude of the current. One of these effects, the accel- G	5 or of RGS subtypes (RGS7, RGS11), which belong
to the same subfamily of RGS proteins as RGS9-2. In-eration of deactivation kinetics, is consistent with the
classical concept that RGS proteins stimulate the creased levels of RGS9-2, based on our in vivo behav-
ioral data, would be expected to diminish D2 signaling.GTPase activity of the Gi subunits through which D2
Hence, the upregulation of RGS9-2 by cocaine couldreceptors signal (Dohlman and Thorner, 1997; Berman
represent a homeostatic response of D2 receptor-con-and Gilman, 1998; De Vries et al., 2000). To some extent,
taining striatal neurons to excessive dopaminergicthe increased rate constant for activation also derives
transmission. This adaptation would therefore be ex-from the fact that equilibrium is approached more rapidly
pected to diminish the animal’s subsequent respon-if channels close more quickly. However, that steady-
siveness to cocaine. Reduced responsiveness or “toler-state amplitudes show little or no decrease in the pres-
ance” to the behavioral effects of cocaine is seen inence of RGS9-2 is a well-known paradox of RGS protein
human addicts and is thought to contribute to escalatingaction (Doupnik et al., 1997; Zerangue and Jan, 1998;
patterns of cocaine use, particularly during binges ofKovoor et al., 2000; Kovoor and Lester, 2002; Zhang
drug administration. Our data, therefore, implicate upreg-et al., 2002). According to present concepts, there is
ulation of RGS9-2 as one mechanism responsible forprobably a “precoupled” macromolecular complex or
this effect. It is interesting that the cocaine-induced in-“scaffold” comprising the D2 receptor, the G	 trimer,
crease in RGS9-2 immunoreactivity was not associatedRGS9-2, and an effector (such as a GIRK channel), in-
with an increase in RGS9-2 mRNA expression. This ob-volving direct contacts among several component pro-
servation raises the possibility that RGS9-2 may be regu-teins, with the result that RGS9-2 shapes both kinetic
lated posttranslationally, although this requires furtherand steady-state aspects of signaling through the D2
investigation.receptor (Ross and Wilkie, 2000; Kovoor and Lester,
G protein-coupled receptors undergo a complex pro-2002; Zhang et al., 2002; Peleg et al., 2002). Importantly,
cess of desensitization upon prolonged exposure to anfor the subsecond agonist pulses that characterize syn-
agonist. The best-established mechanism underlyingaptic transmission, the expected overall result is to de-
this process involves phosphorylation of the receptorscrease the overall current, which would dampen average
by G protein receptor kinases and the subsequent inter-levels of D2 receptor signaling (Doupnik et al., 1997).
action of the receptors with arrestins (reviewed in Lef-Consistent with the hypothesis that RGS9-2 nega-
kowitz, 1998). Indeed, recent work has shown that micetively modulates dopamine signaling are our findings
that lack arrestin-2 show reduced desensitization to thethat RGS9 knockout mice show heightened behavioral
cellular effects of opiates (which act on Gi-coupled re-responses to amphetamine and to cocaine. The height-
ceptors) and reduced tolerance to the analgesic effectsened locomotor responses were observed for both
of opiates after repeated exposure (Bohn et al., 1999,acute and repeated drug exposure. RGS9 mutants also
2000). The in vitro actions of RGS proteins suggest thatshowed increased sensitivity to the rewarding effects
they, too, may contribute to receptor desensitizationof cocaine as measured by place conditioning, which
(reviewed in Dohlman and Thorner, 1997; Nestler andinvolves repeated drug exposures. Furthermore, we pro-
Aghajanian, 1997; Berman and Gilman, 1998; Potenzavided direct evidence for enhanced dopamine receptor
et al., 1999; Gold et al., 2003). Results of the presentsignaling in the RGS9 knockouts: the mutants showed
study provide the first in vivo evidence consistent withgreater locomotor responses to apomorphine, as well
this possibility. It will be interesting in subsequent stud-as greater D2-receptor-mediated inhibition of adenylyl
ies to evaluate a role for RGS proteins in other in vivocyclase in striatal extracts.
systems of receptor desensitization and tolerance; forThe finding that a protein highly enriched in striatal
example, as seen with chronic opiate exposure. Resultsregions can influence behavioral responses to psycho-
of the present study also raise the possibility that drugsstimulants is not surprising, since these regions are
targeting RGS9-2 function might be useful in the treat-known to play a central role in mediating both the loco-
ment of psychostimulant and possibly other drug addic-motor activating and rewarding responses of the drugs.
tions.The dorsal striatum contributes to the locomotor effects
The results presented here further demonstrate thatof the drugs, whereas the nucleus accumbens is in-
behavioral plasticity to drugs of abuse can be linked tovolved in both the locomotor and rewarding effects (Self
specific proteins that modulate cellular responses to theand Nestler, 1998; Wise, 1998). These drugs act by in-
drugs (Nestler, 2001). Thus, RGS9-2 levels are increasedcreasing dopaminergic transmission in striatal regions,
in striatum by chronic exposure to cocaine, and modu-either by inhibiting dopamine reuptake (cocaine) or stim-
lating RGS9-2 levels in animals alters their behavioralulating dopamine release (amphetamine). The precise
responses to cocaine. Together, these results establishcontribution of D1 and D2 receptor subtypes in mediat-
a functional interaction between RGS9-2 and drugs ofing these responses remains unclear, although both re-
abuse and contribute toward a more complete under-ceptors are clearly involved (Self and Nestler, 1998;
standing of the molecular and cellular mechanisms byWise, 1998; Self et al., 1998). Our results would suggest
which repeated cocaine exposure causes a state of ad-that RGS9-2 selectively modulates responses mediated
diction.via the D2 receptor.
We also found that chronic, but not acute, administra-
Experimental Procedures
tion of cocaine increases levels of RGS9-2 immunoreac-
tivity in the nucleus accumbens and dorsal striatum. All animal procedures were in accordance with the NIH Guide for
the Care and Use of Laboratory Animals and were approved by ourImportantly, this increase was observed with chronic
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Institutional Animal Care and Use Committee. Male Sprague-Dawley lyzed by two-way ANOVA (HSV  time) with Bonferroni post hoc
test.rats (initial weight 250 g; Charles River, Kingston RI) and RGS9
mutant mice (Chen et al., 2000) and their wild-type littermates (10–14 For mice, locomotor activity was determined in an automated
system in which the activity chambers were plastic cages (12 weeks old; see below) were used in these studies. All mice were bred
from heterozygous crossings (mixed 129-B6 background); male and 18  33 cm) with 10 pairs of photocell beams dividing the chamber
into 11 rectangular fields, as described previously (Hiroi et al., 1997).female homozygous null mice and their wild-type littermates were
used. There was no apparent gender difference in subsequent be- Mice were tested at the same time each day by an experimenter
who did not know the genotype of the mice. For acute experiments,havioral analyses. Mice were housed by litter and not by genotype.
The animal colony was climate controlled and kept on a 12 hr light/ animals were habituated to the chambers for 30 min, after which
time they received i.p. injections of saline or of varying doses ofdark cycle. Animals were group housed; food and water was made
available ad libitum. amphetamine, cocaine, or apomorphine, and locomotor activity was
assessed for an additional 30 min. For chronic experiments, animals
were placed in the chambers immediately after an i.p. saline injection
Generation and Use of HSV Constructs on the first 3 days (S1–S3). Horizontal activity was then measured
HSV vectors containing RGS9-2, RGS9-1, RGS4, and LacZ were for 10 min. On days 4–8 (C1–C5), animals were given cocaine (7.5
prepared as described (Neve et al., 1997). The average titer of the mg/kg i.p.) and activity was measured for 10 min. The short time
purified virus stocks was 108 infectious units/l. Rats received periods used for rats and mice have been shown in previous studies
unilateral microinjections (2 l) of HSV vectors delivered over 10 to avoid the potentially confounding effects of stereotypy in mea-
min into rat nucleus accumbens by stereotaxic surgery; sucrose sures of ambulatory locomotor activity (Carlezon et al., 1997; Kelz
vehicle was microinjected into the contralateral side. Half of the et al., 1999; Hiroi et al., 1997).
animals received HSV injections on the right side and half on the
left side. Each HSV vector caused roughly comparable expression
Conditioned Place Preference Assayof the encoded transgene as assessed by in situ hybridization. As
The conditioned place preference assay used in this study has beendemonstrated in several previous studies (Carlezon et al., 1997,
described elsewhere (Carlezon et al., 1997; Kelz et al., 1999; Hiroi1998; Neve et al., 1997; Kelz et al., 1999), HSV injections were not
et al., 1997). During the first session, mice were allowed to exploreassociated with detectable toxicity: Nissl staining was indistinguish-
the three chambers (two large chambers with a small chamber inable on the side that received the HSV vector versus sucrose vehicle.
between) of the place conditioning apparatus freely for 20 min.Intracranial surgery was performed, using a 26 gauge hamilton
Neither mutant mice nor their wild-type littermates showed a biassyringe, exactly as described (Carlezon et al., 1997). The following
to either of the two large chambers. The following three sessionscoordinates were used for nucleus accumbens: anteroposterior,
were used for conditioning: mice were alternatively confined to ei-1.8 mm posterior to bregma; lateral/medial,2.5 mm from midline;
ther of the two large chambers immediately after administration ofand dorsal/ventral, 6.8 mm below dura; the injection syringe was
cocaine (10 mg/kg i.p.) or saline for 20 min. On the fifth session, theangled at 10 from the midline. The syringe was left in place for 5
mice were placed in the central chamber and were allowed to movemin before injection.
freely among the three chambers for 20 min. The time they spent in
the cocaine-paired chamber minus that in the saline-paired chamber
Rotation Behavior in Rats provides a measure of place conditioning.
Animals were injected unilaterally with an HSV vector into the nu-
cleus accumbens. HSV-LacZ was injected on the other side of the Cocaine Self-Administration
brain as a control. Three and four days after surgery, when transgene Cocaine self-administration was carried out according to published
expression is maximal, animals were given apomorphine (1 mg/kg procedures (Self et al., 1998). Briefly, male Sprague-Dawley rats
s.c.), quinpirole (1 mg/kg i.p.), or SKF-81297 (3 mg/kg s.c.) and weighing 300–325 g were randomized into two groups (saline and
placed in a large (16 in diameter) round chamber for a period of cocaine) and trained to respond for saline or cocaine infusions in
40 min after drug administration. All rotations were recorded on 15 daily 4 hr test sessions (5–6 days/week). Animals were killed
videotape and the net rotation asymmetry was calculated. At the 16–20 hr after the last self-administration session and the brains
time of scoring the behavior, the researcher was blind to the orienta- were rapidly dissected in ice-cold artificial CSF.
tion (side of brain) of the HSV injections. All animals were pretested
with apomorphine (1 mg/kg) for 3 days (each with a day interval
In Situ Hybridization and Immunohistochemistrybetween); animals that showed no directional bias and a robust
Isotopic in situ hybridization for localization of HSV-RGS9-2 overex-locomotor response were used for the HSV injections; more than
pression in brain was performed exactly as described (Gold et al.,80% of all pretested animals were used for subsequent experiments.
1997). For double-labeling flourescent in situ hybridization, rat brainsData were calculated as percentage of total turns away from HSV-
were rapidly frozen on dry ice and stored at 80C. Coronal 14 mLacZ and expressed as mean percentages; data from days 3 and
sections through striatum (1.6 to 0.9 mm rostral to bregma) were4, which were indistinguishable, were combined. After testing, rats
cryosectioned and thaw-mounted onto Superfrost Plus glass slideswere perfused with paraformaldehyde, and the brains analyzed by
(Fisher, Pittsburgh, PA). Sections were pretreated by fixation inNissl to confirm the placement of the injection needle and the lack
ice-cold 4% paraformaldehyde (20 min), dehydrated in increasingof toxicity. Some sections were examined for expression of RGS9-2
concentrations of ethanol, and allowed to air dry. Sections wereby in situ hybridization (Rahman et al., 1999) or 	-galactosidase by
rehydrated, acetylated for 5 min, dehydrated, and air-dried as be-immunohistochemistry (Carlezon et al., 1997).
fore, hybridized coverslipped in buffer containing 50% formamide,
5 SSC, 5 Denhardts, 250 g/ml yeast RNA, 0.5 mg/ml salmon
testes DNA, 200–300 ng/ml RNA probe overnight at 65C, in a humid-Locomotor Activity Assays
For rats, spontaneous locomotor activity was monitored in a circular ified chamber. Slides were washed to a stringency of 0.2 SSC at
65C and then blocked with 5% normal rabbit IgG and 1% blockingcorridor (10 cm wide and 60 cm in diameter with walls 30 cm high;
Med Associates Inc., St Albans, VT). Four photoelectric cells located reagent (Roche). Digoxigenin-labeled probes were detected first
using a rabbit anti-digoxigenin antibody coupled to horseradish per-equidistantly around the walls of the circles detected an animal’s
horizontal ambulatory activity by way of beam interruptions. Data oxidase (1:200: DAKO). The signal was amplified and detected using
tyramide signal amplification; TSA-direct by deposition of Floures-were recorded via a PC equipped with a customized software (Med
Associates). Separate groups of animals were tested with 10 mg/kg cein (Perkin-Elmer). The HRP conjugated to the anti-digoxigenin
antibody was quenched by H2O2 treatment (3%, 15 min), and the(n  6 per group) and 20 mg/kg (n  12 per group) cocaine. Animals
were randomized into treatment groups (HSV-LacZ and HSV-RGS9- biotin-labeled probes were detected with 1:1000 streptavidin conju-
gated to HRP (Perkin-Elmer) followed by amplification with TSA-2) and habituated to the locomotor apparatus for 2 hr. On the next
day, animals received HSV vectors in the nucleus accumbens shell direct deposition of Cy3 (Perkin-Elmer). The slides were then dehy-
drated and mounted in DPX (Fluka). Biotinylated and digoxigenin-on a stereotaxic frame. Following 2 days of recovery, animals were
tested with cocaine on locomotor activity for 2 hr. Data were ana- labeled antisense riboprobes complementary to RGS9-2, enkepha-
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lin, or substance P were transcribed in vitro using digoxigenin and MgCl2, 1 mM CaCl2, and 5 mM HEPES [pH 7.5]) solution supple-
mented with sodiumpyruvate (2.5 mM) and gentamycin (50 g/ml).biotin in vitro transcription kits (Roche). All three transcripts localized
by FISH in these experiments are striatally abundant mRNAs with All oocytes were injected with 1 ng of cRNA for the D2 receptor,
and 0.02 ng of cRNA each for GIRK1 and GIRK2. Dopamine (1relatively far lower mRNA concentrations in overlying neocortex.
This regional labeling footprint was utilized to assess background M) was used as the dopamine receptor agonist. A valve system
controlled by the data acquisition software pCLAMP 6 (Axon Instru-labeling. In all experiments, the digoxigenin-labeled riboprobes had
very low background signal. The biotinylated-labeled riboprobes ments) was used to control solution changes and to minimize wash-
ing and washout times. Two-electrode voltage clamp recordings ofhad consistently higher background signal, but specific signal was
easily distinguished by subtracting out the background as measured the oocytes were performed 36–72 hr after cRNA injection. Mem-
brane potential was clamped at 80 mV using a Geneclamp 500in neocortex. As an additional tool for assessing background label-
ing, all experiments included control conditions, where sections amplifier (Axon Instruments) and pCLAMP 6 software. Electrodes
were filled with 3 M KCl and had resistances of 0.5–1.5 M. Towere mock-hybridized with no probe and then processed through
the streptavidin-HRP-TSA amplification. To assess the degree of reveal inward currents through the inwardly rectifying GIRK chan-
nels, recordings were performed in oocyte saline buffer with ele-TSA-mediated crossamplification, single-labeling controls for both
haptens were included in each experiment. No significant differ- vated (16 mM) KCl concentration (other components: 82 mM NaCl,
1 mM MgCl2, 1 mM CaCl2, and 5 mM HEPES [pH 7.5]).ences in the numbers of RGS9 or peptide mRNA positive cells per
unit area were found between the double- and single-labeled condi-
tions, indicating insignificant amounts of crossamplification. As an Dopamine Receptor Binding and Adenylyl Cyclase Studies
additional control for crossamplification between the two hapten- Published methods were used for radioligand binding studies (Lued-
labeled riboprobes, double-labeling for substance P and enkephalin tke et al., 2000). The D1-like selective radioligand, 3H SCH 23390
mRNAs was conducted with both possible hapten-labeled ribo- (PerkinElmer Life Sciences, Boston, MA), was used to quantify D1
probe combinations. In either case, 10% of substance P cells receptors, while the D2-like selective radioligand, 125I-IABN, was
were colocalized with enkephalin cells. Taken together, these con- used to quantify D2-like receptors. Nonspecific binding was defined
trol experiments suggest that crossamplification could not account by including ()-butaclamol (2.5 M) in the binding assays. D1 bind-
for an appreciable number of false positives for a given riboprobe. ing assays were performed in the presence of 100 nM ketanserin,
Colocalization was assessed using a Zeiss LSM510 confocal micro- a serotonin 5HT2 receptor antagonist. Protein was quantified using
scope. Background labeling for both the Cy3 and flourescein signal a BCA protein reagent kit (Pierce, Rockford, IL) with bovine serum
was established in the overlying neocortex for each section. Then, albumin as the standard. Estimates of Kd and Bmax values were
single- and double-labeled cells were counted by an observer blind obtained using unweighted linear regression analysis of transformed
to the experimental conditions, with an average of 125 cells sampled data.
per section and two sections sampled per rat. For measures of adenylyl cyclase activity, membranes were pre-
Double-labeling immunohistochemistry of mouse striatum was pared from striatum of RGS9 mutant mice and their wild-type lit-
sequentially performed with anti-D1 receptor polyclonal rabbit anti- termates according to standard methods and resuspended in 50
serum, anti-D2 receptor polyclonal rabbit antiserum (Research & mM Tris-HCl, 100 mM NaCl, 3 mM MgCl2, and 0.2 mM EGTA. Aliquots
Diagnostics Antibodies, San Francisco, CA), and RGS9 polyclonal (containing 3–5 g protein) were incubated with a maximal concen-
goat antiserum (Santa Cruz Biotechnologies, CA) by use of standard tration of quinelorane (10 M) for 15 min at 30C in the above buffer
procedures (Carlezon et al., 1997). Primary receptor antibodies were containing 50 M ATP, [-32P]ATP (1.5 Ci), 0.2 mM DTT, 0.01%
labeled with Alexa 488-conjugated anti-rabbit IgG made in sheep (wt/vol) BSA, 50 M cAMP, 50 M GTP, 3 mM papaverine, 5 mM
and RGS9 antibody with Cy5-conjugated anti-goat IgG made in phosphocreatine, and 20 units/ml creatine phosphokinase in a final
donkey. volume of 100 l. The reaction was terminated by boiling in a water
bath for 2 min. [32P]cAMP was isolated by the method of Salomon
(1979).Brain Dissections and Western Blotting
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